New Research On Corcept Therapeutics Inc.'s Korlym® For Patients With Cushing's Syndrome To Be Presented At ICE/ENDO 2014

Published: Jun 20, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, IL--(Marketwired - June 19, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym® (mifepristone) will be presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).

The research, including results of a long-term extension phase of Corcept's multicenter, open-label SEISMIC study of Korlym, will be presented at the conference, taking place at the McCormick Place West Convention Center in Chicago from June 21-24. Korlym is a once-daily oral treatment for patients with Cushing's syndrome who have glucose intolerance and have failed or cannot have surgery.

"Cushing's syndrome, which is caused by excessive cortisol activity, is a serious condition that has a debilitating impact on all aspects of patients' lives. The disease often significantly affects patients' metabolism, leading to extreme weight gain with abnormal fat deposits, impaired glycemic control including type 2 diabetes, muscle weakness and, commonly, psychiatric symptoms," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Because Cushing's syndrome may be a chronic disease, it is important to monitor patients taking Korlym over time. The long-term extension study of SEISMIC includes data from patients who had been receiving treatment for as long as 3.5 years."

Cushing's syndrome is the result of excessive cortisol activity throughout the body. Cortisol is a hormone made in the adrenal glands that performs vital tasks such as regulating the metabolism of proteins, carbohydrates and fats. Cushing's syndrome afflicts 20,000 people in the United States, with approximately 3,000 to 4,000 new cases each year. Approximately half of these patients are cured by surgery.

The following abstracts highlight new research on mifepristone:

Date      Session   Poster    Title                           Authors       
          Time      Number                                                  
Saturday, 11:30am-  OR02-2    Late-Night Salivary Cortisol    Ty Brian      
 June 21, 1:00pm              for the Diagnosis of Recurrent  Carroll, MD;  
 2014                         Cushing's Disease: Evidence of  Bradley R     
                              Clinical Benefit from Early     Javorsky, MD; 
                              Detection                       James W       
                                                              Findling, MD  
          1:00-     SAT-0671  Clinical Management in a Female Elizabeth E   
          3:00pm              with Persistent Cushing's       King, MD;     
                              Disease Treated with            Simone M      
                              Mifepristone for Four Years     Howell, RN,   
Sunday,   1:00-     SUN-0750  Effect of Mifepristone on       Vijay Babu    
 June 22, 3:00pm              Cushing's syndrome Secondary to Balakrishnan; 
 2014                         Bilateral Adrenal Adenomas: A   Pankaj Sharda,
                              Case Presentation               MBBS, MD;     
                                                              Elias Said    
                                                              Siraj, MD     
Monday,   1:00-     MON-0439  Improved Activities of Daily    Daphne T      
 June 23, 3:00pm              Living, Normal Mood and Quality Adelman, BSN, 
 2014                         of Life: 4 Years of Treatment   MBA; Simone M 
                              Data in a Premenopausal Woman   Howell, RN,   
                              with Cushing's Disease          CCRA          
                    MON-0592  A Case Report of a 37 y/o Woman Howard A      
                              Diagnosed with Cushing's        Brand, MD;    
                              Disease Presenting As Pituitary Kimberly      
                              Apoplexy after Multiple         Calcagno, MA; 
                              Treatment Failures Effectively  Michele       
                              Responds to Mifepristone        Lamerson, RN, 
                                                              MS, CPNP      
                    MON-0595  Discontinuation of Insulin,     Kevin C.J.    
                              Oral Antidiabetic and           Yuen, MD, FRCP
                              Antihypertensive Medications in (UK); Harold I
                              a Patient with Cushing's        Magazine, PhD 
                              Disease Following Mifepristone                
                              (MIFE) Therapy                                
                    MON-0598  Mifepristone for Refractory     Audrey        
                              Cushing's Syndrome in a Patient Elisabeth     
                              with CKD Hyperkalemia           Arzamendi, MD;
                              Undergoing Surgical Exodontia   Alison Marie  
                              and Weight Loss:                Semrad, DO    
                              Recommendations for                           
                              Clinical/Biochemical Monitoring               
                              and Perioperative Dosing                      
                    MON-0663  Persistent Weight Loss in       Henry G. Fein,
                              Patients Treated with           MD; T. Brooks 
                              Mifepristone (MIFE) for         Vaughan III,  
                              Cushing's Syndrome: Results     MD; Coleman   
                              from the Seismic & Long Term    Gross; Dat    
                              Extension Studies               Nguyen        

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that regulate the effects of the stress hormone cortisol on the body. The FDA has approved the company's first drug, Korlym® (mifepristone) 300 mg Tablets, a glucocorticoid receptor antagonist, as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Corcept is exploring mifepristone (the active ingredient in Korlym) as a treatment for triple-negative breast cancer with a multi-center, Phase I clinical study currently underway in patients with metastatic or locally advanced unresectable breast cancer. It is also supporting investigator-led clinical studies of mifepristone in the treatment of ovarian cancer and castration-resistant prostate cancer. The company has a portfolio of selective glucocorticoid-receptor (GR) antagonists that block the effects of cortisol but not progesterone. It owns or has licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders and triple-negative breast cancer. It also holds composition of matter patents for its selective GR antagonists.

Investor Contact
Charles Robb
Corcept Therapeutics Incorporated
Chief Financial Officer
Email Contact

Media Contact
Brian Baxter for Corcept
Lazar Partners Ltd.
Email Contact

Help employers find you! Check out all the jobs and post your resume.

Back to news